
Leading publicly listed pharmaceutical manufacturer Renata PLC has continued its international market expansion by launching a new medication in the Netherlands. The company disclosed the development through an official filing on the Dhaka Stock Exchange (DSE) website on Tuesday, November 17, 2026.
According to the disclosure, Renata has commenced marketing Amantadine Hydrochloride 100 mg capsules—used to alleviate symptoms of Parkinson’s disease—in the Dutch market, packaged in boxes of 56 capsules. The same formulation is marketed domestically in Bangladesh under the brand name ‘Montadin’. The exported medication is manufactured at Renata’s Rajendrapur production facility, which holds European Union Good Manufacturing Practice (EU-GMP) certification, enabling the company to strengthen its footprint across regulated European markets.
Read nextBangladesh Bank Imposes New Restrictions on Destination-Charge Payments for Imported GoodsFinancially, Renata posted strong growth in the first quarter (Q1) of the current fiscal year, with Earnings Per Share (EPS) climbing 37 percent year-on-year to Tk 8.87, up by Tk 2.40 from Tk 6.47 in the corresponding period last year. As of September 30, the company's Net Asset Value Per Share (NAVPS) stood at Tk 339.31. Earlier, Renata’s Board of Directors declared a 55 percent cash dividend for FY 2025–26—matching its FY 2024–25 payout—backed by an annual EPS of Tk 31.76 (up from Tk 19.36) and a June 30 NAVPS of Tk 329.19. Following the November 15 record date, shareholders will vote to approve the dividend at the upcoming Annual General Meeting (AGM) on December 19, 2026.
— Daily Best News Desk • Fearless in the search for truth
Reported by Staff Reporter • Edited by the Daily Best News desk. Send corrections to [email protected].









